Penetrance and Expressivity
On this page
Direct answer
Penetrance counts whether a genotype produces any phenotype at all — an all-or-none, population-level statistic — while expressivity grades how severely that phenotype manifests in an individual who is penetrant. Neurofibromatosis type 1 is the textbook pairing: penetrance is virtually complete by adulthood (nearly every mutation carrier shows some sign), yet expressivity swings from six café-au-lait patches to plexiform neurofibromas and optic glioma within one family. Retinoblastoma illustrates incomplete penetrance (a carrier parent with normal retinas and two affected children), hereditary haemochromatosis illustrates low penetrance in a common genotype, and Huntington disease illustrates age-dependent penetrance rising with the CAG repeat count. Modifier genes, environment, epigenetics and chance explain both phenomena — which is why identical genotypes never guarantee identical patients.
What you must remember
- Definitions, stated precisely: penetrance is the proportion of individuals with a given genotype who show any phenotype; expressivity is the degree or spectrum of that phenotype among penetrant individuals — a distinction that begins most vivas on this topic.
- The NF1 exemplar: near-complete penetrance with famously variable expressivity; about half of cases are de novo — so an unaffected parent does not exclude the diagnosis in the child, a counselling combination examiners quote together.
- Incomplete penetrance exemplars: retinoblastoma (about 90 per cent penetrance — unaffected carriers exist), BRCA1 and BRCA2 breast cancer risk (commonly quoted as roughly half to three-quarters of carriers developing breast cancer by seventy, versus a much lower population baseline), and hereditary haemochromatosis C282Y homozygotes, of whom only a minority express clinical iron overload.
- Age- and sex-dependent penetrance: Huntington disease (complete penetrance with 40 or more CAG repeats; reduced penetrance in the 36 to 39 range), hereditary haemochromatosis expressing less in menstruating women — two modifiers every student should be able to name.
- Expressivity exemplars: Marfan syndrome (neonatal lethal to near-silent), osteogenesis imperfecta (type 1 mild against type 2 lethal, from different collagen variants), and the polydactyly family of disorders.
- Mechanisms of variation: modifier genes in the background genome, environmental triggers (diet in haemochromatosis, sun in naevoid syndromes), epigenetic effects, and stochastic developmental events.
- Counselling consequence: penetrance sets the probability that a genotype will show itself; expressivity prevents any promise about severity — both must be stated in a pre-test counselling session.
Counselling a family across both concepts
A 30-year-old woman with café-au-lait patches and axillary freckling has NF1; her father has a single plexiform neurofibroma and her brother has only iris hamartomas (Lisch nodules). The family demonstrates the pair of concepts in one room: all three are penetrant — the genotype shows in each — but expressivity orders them from skin-deep to disfiguring. Her reproductive counselling now requires two honest numbers: each child of hers has a 50 per cent chance of inheriting the mutation, and, given near-complete penetrance, an inheriting child will show some manifestation — but no test can promise severity, because expressivity within NF1 families varies precisely as it has among these three relatives.
Contrast the second scenario: a woman whose mother died of breast cancer at 46 tests positive for a BRCA1 pathogenic variant. Her own risk is high but not certain — incomplete, age-dependent penetrance — and her management is surveillance and risk-reduction rather than certainty.
Where the exam sets its traps
The phrasing trap leads: examiners ask for "a condition with complete penetrance but variable expressivity" — the expected single answer is NF1 — and then its mirror, "incomplete penetrance," which retinoblastoma or BRCA satisfies. Second, students describe penetrance as a property of the gene; it is a property of the genotype in a population, measured at a stated age — Huntington disease at 30 and at 70 gives two different numbers, and saying so earns the extra mark. Third, incomplete penetrance is not the same as mild expressivity: the retinoblastoma carrier with normal retinas shows no phenotype at all (non-penetrance), while the NF1 patient with only Lisch nodules is penetrant with mild expressivity — a distinction that sounds pedantic until an examination question hangs on it.
Frequently asked questions
What is the difference between penetrance and expressivity?
Penetrance is whether a genotype shows any phenotype in a population, whereas expressivity is how severe or extensive that phenotype is in a penetrant individual.
Which disorder is the classic example of complete penetrance with variable expressivity?
Neurofibromatosis type 1 — virtually all adult mutation carriers show features, ranging from café-au-lait macules to plexiform neurofibromas.
Why does hereditary haemochromatosis show low penetrance?
Many C282Y homozygotes never accumulate clinically significant iron, because dietary, menstrual and modifier genetic factors blunt expression of the genotype.
What is age-dependent penetrance, with an example?
Penetrance that rises with age — Huntington disease is essentially fully penetrant with 40 or more CAG repeats, but only after decades of life, so a normal 30-year-old carrier is not reassured.
Why must expressivity be discussed in genetic counselling even when penetrance is complete?
Because the severity, age at onset and complications of a completely penetrant disorder remain unpredictable, as NF1 families illustrate within a single sibship.